18 and older, any sex, with Short Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Subjects Achieving a 20% Reduction at Week 28Primary· 28 weeks
For those subjects who received teduglutide (0.05 or 0.10 mg dose) in Study 004 and the same in Study 005, Parenteral Nutrition (PN) Use at Week 28 was compared to the Baseline Visit of Study 004 to calculate the 20% reduction in PN Use. For those subjects who received placebo in Study 004 and either teduglutide 0.05 or 0.10 mg dose in Study 005, PN Use at Week 28 was compared to the use of PN at Week 24 of Study 004 to calculate the 20% reduction in PN Use.
Group
Value
95% CI
Placebo/0.05
5
Placebo/0.10
3
0.05/0.05
17
0.10/0.10
14
Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) UseSecondary· 6 months
Number of Subjects Who Achieved at Least a One-Day Reduction in Parenteral Nutrition (PN) Use (Responder Status is Yes or No)
Response Status: Yes
Group
Value
95% CI
Placebo/0.05
4
Placebo/0.10
2
0.05/0.05
17
0.10/0.10
10
Response Status: No
Group
Value
95% CI
Placebo/0.05
2
Placebo/0.10
5
0.05/0.05
8
0.10/0.10
17
Adverse events — posted to ClinicalTrials.gov
Time frame: 28 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07197944 — Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
· Phase 3
· recruiting
NCT05535361 — A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in A
· NA
· recruiting
NCT06973304 — A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
· Phase 3
· recruiting
NCT06326645 — Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
· EARLY_PHASE1
· recruiting
NCT06771505 — SBS DISK- Creation of a Quality of Life Tool for Short Bowel Patients Compared With a Validated Quality of Life Question
· recruiting
Other Shire trials
Trials by the same sponsor.
NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India
· Phase 4
· recruiting
NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism
· Phase 3
· withdrawn
NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease
· Phase 3
· terminated
NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India
· completed
NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
· Phase 4
· withdrawn
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shire
Last refreshed: 2 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00172185.